Skip to main content
SpringerLink
Log in
Book cover

Graves' Disease pp 213–222Cite as

Treatment of Hyperthyroidism in Patients with Graves’ Orbitopathy

  • Chapter

  • 2227 Accesses

Abstract

Hyperthyroidism due to Graves’ disease can be treated by antithyroid drugs (ATDs), radioiodine (RAI), or thyroidectomy. None of the treatments targets pathogenetic mechanisms of the disease. Graves’ orbitopathy (GO), the most frequent extrathyroidal manifestation of Graves’ disease, is present in about 25 % of newly diagnosed Graves’ patients, and rarely progresses over time. Neither ATDs nor thyroidectomy appear to affect the natural course of GO. At variance, RAI may cause de novo occurrence or progression of preexisting GO in a minority of patients, especially if smokers. In patients with mild GO, all the treatments for hyperthyroidism can be used safely. However, in most patients receiving RAI treatment, steroid prophylaxis using low-dose prednisone for a few weeks is advisable to prevent RAI-associated progression of GO. In the few patients with sight-threatening eye disease, management of GO has an absolute priority, and hyperthyroidism should be conservatively treated with ATDs until GO is cured. In patients with moderate-to-severe and active GO, who must be treated as soon as possible by immunosuppression, the choice of a conservative approach (ATDs) or an ablative treatment (RAI, thyroidectomy, total thyroid ablation) for thyroid dysfunction remains an important and unsolved dilemma. In patients whose GO has been cured or inactivated, any treatment for hyperthyroidism can be safely used.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   159.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Bartalena L. Diagnosis and management of Graves disease: a global overview. Nat Rev Endocrinol. 2013;9:724–34.

    Article  CAS  PubMed  Google Scholar 

  2. Bartalena L, Tanda ML. Clinical practice, Graves’ ophthalmopathy. N Engl J Med. 2009;360:994–1001.

    Article  CAS  PubMed  Google Scholar 

  3. Tanda ML, Piantanida E, Liparulo L, Veronesi G, Lai A, Sassi L, Pariani N, Gallo D, Azzolini C, Ferrario M, Bartalena L. Prevalence and natural history of Graves’ orbitopathy in a large series of patients with newly diagnoses Graves’ hyperthyroidism seen at a single center. J Clin Endocrinol Metab. 2013;98:1443–9.

    Article  CAS  PubMed  Google Scholar 

  4. Laurberg P, Berman DC, Bülow Pedersen I, Andersen S, Carlé A. Incidence and clinical presentation of moderate to severe Graves’ orbitopathy in a Danish population before and after iodine fortification of salt. J Clin Endocrinol Metab. 2012;97:2325–32.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  5. Piantanida E, Tanda ML, Lai A, Sassi L, Bartalena L. Prevalence and natural history of Graves’ orbitopathy in the XXI century. J Endocrinol Invest. 2013;36:444–9.

    CAS  PubMed  Google Scholar 

  6. Bartalena L. Prevention of Graves’ ophthalmopathy. Best Pract Res Clin Endocrinol Metab. 2012;26:371–9.

    Article  PubMed  Google Scholar 

  7. Wiersinga WM. Smoking and thyroid. Clin Endocrinol (Oxf). 2013;79:145–51.

    Article  CAS  Google Scholar 

  8. Pfeilschifter J, Ziegler R. Smoking and endocrine ophthalmopathy: impact of smoking severity and current versus lifetime cigarette consumption. Clin Endocrinol (Oxf). 1996;45:477–81.

    Article  CAS  Google Scholar 

  9. Kohrle J. Pathophysiological relevance of selenium. J Endocrinol Invest. 2013;36 Suppl 10:1–7.

    CAS  PubMed  Google Scholar 

  10. Marcocci C, Bartalena L. Role of oxidative stress and selenium in Graves’ hyperthyroidism and orbitopathy. J Endocrinol Invest. 2013;36 Suppl 10:15–20.

    CAS  PubMed  Google Scholar 

  11. Marcocci C, Kahaly GJ, Krassas GE, Bartalena L, Prummel M, Stahl M, Altea MA, Nardi M, Pitz S, Boboridis K, Sivelli P, von Arx G, Mourits MP, Baldeschi L, Bencivelli W, Wiersinga M, For the European Group on Graves’ Orbitopathy. Selenium and the course of mild Graves’ orbitopathy. N Engl J Med. 2011;364:1920–31.

    Article  CAS  PubMed  Google Scholar 

  12. Bartalena L, Pinchera A, Marcocci C. Management of Graves’ ophthalmopathy: reality and perspectives. Endocr Rev. 2000;21:168–99.

    CAS  PubMed  Google Scholar 

  13. Emiliano AB, Governale L, Parks M, Cooper DS. Shifts in propylthiouracil and methimazole prescribing practices: antithyroid drug use in the United States from 1991 to 2008. J Clin Endocrinol Metab. 2008;95:2227–33.

    Article  Google Scholar 

  14. Burch HB, Burman KD, Cooper DS. A 2011 survey of clinical practice patterns in the management of Graves’ disease. J Clin Endocrinol Metab. 2012;97:4549–58.

    Article  CAS  PubMed  Google Scholar 

  15. Bahn RS, Burch HB, Copper DS, Garber JR, Geenlee MC, Klein I, Laurberg P, McDougall IR, Montori VM, Rivkees SA, Ross DS, Sosa JA, Stan MN. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid. 2011;21:591–646.

    Google Scholar 

  16. Prummel MF, Wiersinga WM, Mourits MP, Koornneef L, Berghout A, van der Gaag R. Amelioration of eye changes of Graves’ ophthalmopathy by achieving euthyroidism. Acta Endocrinol (Copenh). 1989;121 suppl 2:185–9.

    Google Scholar 

  17. Prummel MF, Wiersinga WM, Mourits MP, Koornneef L, Berghout A, van der Gaag R. Effect of abnormal thyroid function on the severity of Graves’ ophthalmopathy. Arch Intern Med. 1990;150:1098–101.

    Article  CAS  PubMed  Google Scholar 

  18. Bartalena L, Baldeschi L, Dickinson AJ, Eckstein A, Kendall-Taylor P, Marcocci C, Mourits M, Perros P, Boboridis K, Boschi A, Currò N, Daumerie C, Kahaly GJ, Krassas GE, Lane CM, Lazarus JH, Marinò M, Nardi M, Neoh C, Orgiazzi J, Pearce S, Pinchera A, Pitz S, Salvi M, Sivelli P, Stahl M, von Arx G, Wiersinga WM. Consensus statement of the European Group on Graves’ orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol. 2008;158:273–85.

    Article  CAS  PubMed  Google Scholar 

  19. Ross DS. Radioiodine therapy for hyperthyroidism. N Engl J Med. 2011;364:542–50.

    Article  CAS  PubMed  Google Scholar 

  20. Tallstedt L, Lundell G, Torring O, Wallin G, Ljunggren J-G, Blomgren H, Taube A, The Thyroid Study Group. Occurrence of ophthalmopathy after treatment for Graves’ hyperthyroidism. N Engl J Med. 1992;326:1733–8.

    Article  CAS  PubMed  Google Scholar 

  21. Bartalena L, Marcocci C, Bogazzi F, Manetti L, Tanda ML, Dell’Unto E, Bruno-Bossio G, Nardi M, Bartolomei MP, Lepri A, Rossi G, Martino E, Pinchera A. Relation between therapy for hyperthyroidism and the course of Graves’ ophthalmopathy. N Engl J Med. 1998;338:73–8.

    Article  CAS  PubMed  Google Scholar 

  22. Acharya SH, Avenell A, Philip S, Burr J, Bevan JS, Abraham P. Radioiodine therapy for Graves’ disease and the effect on ophthalmopathy – a systematic review. Clin Endocrinol (Oxf). 2008;69:943–50.

    Article  Google Scholar 

  23. Traisk F, Tallstedt L, Abraham-Nordling M, Andersson T, Berg G, Calissendorf J, Hallengren B, Hedner P, Lantz M, Nystrom E, Ponjavic V, Taube A, Torring O, Wallin G, Asman P, Lundell G, Thyroid Study Group of TT 96. Thyroid-associated ophthalmopathy after treatment for Graves’ hyperthyroidism with antithyroid drugs or iodine-131. J Clin Endocrinol Metab. 2009;94:3700–7.

    Article  CAS  PubMed  Google Scholar 

  24. Bartalena L, Marcocci C, Tanda ML, Manetti L, Dell’Unto E, Bartolomei MP, Nardi M, Martino E, Pinchera A. Cigarette smoking and treatment outcomes in Graves’ ophthalmopathy. Ann Intern Med. 1998;129:632–5.

    Article  CAS  PubMed  Google Scholar 

  25. Tallstedt L, Lundell G, Blomgren H, Bring J. Does early administration of thyroxine reduce the development of Graves’ ophthalmopathy after radioiodine treatment? Eur J Endocrinol. 1994;130:494–7.

    Article  CAS  PubMed  Google Scholar 

  26. Perros P, Kendall-Taylor P, Neoh C, Frewins S, Dickinson S. A prospective study of the effects of radioiodine therapy for hyperthyroidism in patients with minimally active Graves’ ophthalmopathy. J Clin Endocrinol Metab. 2005;90:5321–3.

    Article  CAS  PubMed  Google Scholar 

  27. Bartalena L, Marcocci C, Bogazzi F, Panicucci M, Lepri A, Pinchera A. Use of corticosteroids to prevent progression of Graves’ ophthalmopathy after treatment for Graves’ hyperthyroidism. N Engl J Med. 1989;321:1349–52.

    Article  CAS  PubMed  Google Scholar 

  28. Lai A, Sassi L, Compri E, Marino F, Sivelli P, Piantanida E, Tanda ML, Bartalena L. Lower dose prednisone prevents radioiodine-associated exacerbation of initially mild or absent Graves’ orbitopathy: a retrospective cohort study. J Clin Endocrinol Metab. 2010;95:1333–7.

    Article  CAS  PubMed  Google Scholar 

  29. Grodski S, Stalberg P, Robinson PG, Delbridge LW. Surgery versus radioiodine therapy as definitive management for Graves’ disease: the role of patient preference. Thyroid. 2007;17:157–60.

    Article  PubMed  Google Scholar 

  30. Bergenfelz A, Jansson S, Kristoffersson A, Matensson H, Rienhér E, Wallin G, Lausen J. Complications to thyroid surgery: results as reported in a database from a multicenter audit comprising 3,660 patients. Langenbecks Arch Surg. 2008;393:667–73.

    Article  CAS  PubMed  Google Scholar 

  31. Bartalena L. The dilemma of how to manage Graves’ hyperthyroidism in patients with associated orbitopathy. J Clin Endocrinol Metab. 2011;96:592–9.

    Article  CAS  PubMed  Google Scholar 

  32. Menconi F, Marinò M, Pinchera A, Rocchi R, Mazzi B, Nardi M, Bartalena L, Marcocci C. Effects of total thyroid ablation versus near-total thyroidectomy alone on mild to moderate Graves' orbitopathy treated with intravenous glucocorticoids. J Clin Endocrinol Metab. 2007; 92:1653–8.

    Article  CAS  PubMed  Google Scholar 

  33. De Bellis A, Conzo G, Cennamo G, Pane E, Bellastella G, Colella C, Iacovo AD, Paglionico VA, Sinisi AA, Wall JR, Bizzarro A, Bellastella A. Time course of Graves’ ophthalmopathy after total thyroidectomy alone or followed by radioiodine therapy: a 2-year longitudinal study. Endocrine. 2013;41:320–6.

    Article  Google Scholar 

  34. Moleti M, Violi MA, Montanini D, Trombetta C, Di Bella B, Sturniolo G, Presti S, Alibrandi A, Campennì A, Baldari S, Trimarchi F, Vermiglio F. Radioiodine ablation of post-surgical thyroid remnants after treatment with recombinant human TSH (rhTSH) in patients with moderate-to-severe Graves’ orbitopathy (GO): a prospective, randomized, single-blind clinical trial. J Clin Endocrinol Metab. 2014;99:1783–9.

    Article  CAS  PubMed  Google Scholar 

  35. Leo M, Marcocci C, Pinchera A, Nardi M, Megna L, Rocchi R, Latrofa F, Altea MA, Mazzi B, Sisti E, Profilo MA, Marinò M. Outcome of Graves’ orbitopathy after total thyroid ablation and glucocorticoid treatment: follow-up of a randomized clinical trial. J Clin Endocrinol Metab. 2012;97:E44–8.

    Article  CAS  PubMed  Google Scholar 

  36. Wiersinga WM, Prummel MF. Graves’ ophthalmopathy: a rational approach to treatment. Trends Endocrinol Metab. 2002;13:280–7.

    Article  CAS  PubMed  Google Scholar 

  37. Mourits MP, Prummel MF, Wiersinga WM, Koornneef L. Clinical activity score as a guide in the management of patients with Graves’ ophthalmopathy. Clin Endocrinol (Oxf). 1997;47:9–14.

    Article  CAS  Google Scholar 

  38. Wiersinga WM. Quality of life in Graves’ ophthalmopathy. Best Pract Res Clin Endocrinol Metab. 2012;26:359–37.

    Article  PubMed  Google Scholar 

  39. Zang S, Ponto KA, Kahaly GJ. Intravenous glucocorticoids for Graves’ orbitopathy: efficacy and morbidity. J Clin Endocrinol Metab. 2011;96:320–32.

    Article  CAS  PubMed  Google Scholar 

  40. Bartalena L, Fatourechi V. Extrathyroidal manifestations of Graves’ disease: a 2014 update on medical management. J Endocrinol Invest. 2014;37:691–700.

    Article  PubMed  Google Scholar 

  41. Wakelkamp IM, Baldeschi L, Saeed P, Mourits MP, Prummel MF, Wiersinga WM. Surgical or medical decompression as a first-line treatment in Graves’ ophthalmopathy? A randomized clinical trial. Clin Endocrinol (Oxf). 2005;63:323–8.

    Article  CAS  Google Scholar 

  42. Hegedus L. Treatment of Graves’ hyperthyroidism: evidence-based and emerging modalities. Endocrinol Metab Clin North Am. 2009;38:355–71.

    Article  CAS  PubMed  Google Scholar 

  43. Elbers L, Mourits M, Wiersinga W. Outcome of very long-term treatment with antithyroid drugs in Graves’ hyperthyroidism associated with Graves’ orbitopathy. Thyroid. 2011;21:279–83.

    Article  PubMed  Google Scholar 

  44. Laurberg P, Berman DC, Andersen S, Bulow Pedersen I. Sustained control of Graves’ hyperthyroidism during long-term low-dose antithyroid drug therapy of patients with severe Graves’ orbitopathy. Thyroid. 2011;21:951–6.

    Article  CAS  PubMed  Google Scholar 

  45. Marcocci C, Bruno-Bossio G, Manetti L, Tanda ML, Miccoli P, Iacconi P, Bartolomei MP, Nardi M, Pinchera A, Bartalena L. The course of Graves’ ophthalmopathy is not influenced by near total thyroidectomy: a case-control study. Clin Endocrinol (Oxf). 1999;51:503–8.

    Article  CAS  Google Scholar 

  46. Tanda ML, Lai A, Bartalena L. Relation between Graves’ orbitopathy and radioiodine therapy for hyperthyroidism: facts and unsolved questions. Clin Endocrinol (Oxf). 2008;60:845–7.

    Article  Google Scholar 

  47. Bartalena L, Krassas GE, Wiersinga W, Marcocci C, Salvi M, Daumerie C, Bournaud C, Stahl M, Sassi L, Veronesi G, Azzolini C, Boboridis KG, Mourits MP, Soeters MR, Baldeschi L, Nardi M, Currò N, Boschi A, Bernard M, von Arx G, For the European Group on Graves’ Orbitopathy. Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves’ orbitopathy. J Clin Endocrinol Metab. 2012;97:4454–63.

    Article  CAS  PubMed  Google Scholar 

  48. Tanda ML, Bartalena L. Efficacy and safety of orbital radiotherapy for Graves’ orbitopathy. J Clin Endocrinol Metab. 2012;97:3857–65.

    Article  CAS  PubMed  Google Scholar 

  49. Salvi M, Vannucchi G, Beck-Peccoz P. Potential utility of rituximab for Graves’ orbitopathy. J Clin Endocrinol Metab. 2013;98:4291–9.

    Article  CAS  PubMed  Google Scholar 

  50. Bartalena L. Rituximab, adalimumab, etanercept, tocilizumab – are biologics the future for Graves’ orbitopathy? Ophthal Plast Reconstr Surg. 2014;30(5):420–3.

    Article  PubMed  Google Scholar 

  51. Vitti P, Rago T, Chiovato L, Pallini S, Santini F, Fiore E, Rocchi R, Martino E, Pinchera A. Clinical features of patients with Graves’ disease undergoing remission after antithyroid drug treatment. Thyroid. 1997;7:369–75.

    Article  CAS  PubMed  Google Scholar 

  52. Bahn RS. Mechanisms of disease – Graves’ ophthalmopathy. N Engl J Med. 2010;362:726–38.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  53. Bartalena L, Marcocci C, Lai A, Tanda ML. Graves’ hyperthyroidism of recent onset and Graves’ orbitopathy: to ablate or not to ablate the thyroid? J Endocrinol Invest. 2008;31:578–81.

    Article  CAS  PubMed  Google Scholar 

  54. Ponto KA, Merkesdal S, Hommel G, Pitz S, Pfeiffer N, Kahaly GJ. Public health relevance of Graves’ orbitopathy. J Clin Endocrinol Metab. 2013;98:145–52.

    Article  CAS  PubMed  Google Scholar 

  55. Bartalena L. Graves’ orbitopathy: imperfect treatments for a rare disease. Eur Thyroid J. 2013;2:259–69.

    Article  PubMed Central  PubMed  Google Scholar 

Download references

Acknowledgements

This work was partly supported by the Ministry of Education, University and Research (MIUR, Rome) (grant PRIN n. 2012Z3F7HE_006) and by the University of Insubria at Varese.

Conflicts of interest none to declare.

Author information

Authors and Affiliations

  1. Endocrine Unit, Ospedale di Circolo, University of Insubria, Viale Borri, 57, Varese, 21100, Italy

    Luigi Bartalena M.D.

Authors
  1. Luigi Bartalena M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Luigi Bartalena M.D. .

Editor information

Editors and Affiliations

  1. Mayo Clinic College of Medicine, Division of Endocrinology and Metabolism, Mayo Clinic, Rochester, Minnesota, USA

    Rebecca S. Bahn

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer Science+Business Media New York

About this chapter

Cite this chapter

Bartalena, L. (2015). Treatment of Hyperthyroidism in Patients with Graves’ Orbitopathy. In: Bahn, R. (eds) Graves' Disease. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-2534-6_16

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-2534-6_16

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4939-2533-9

  • Online ISBN: 978-1-4939-2534-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation